CONCISE COMMUNICATION
|
|
- Baldric McKinney
- 6 years ago
- Views:
Transcription
1 1688 CONCISE COMMUNICATION Vertical Transmission of Multidrug-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) and Continued Evolution of Drug Resistance in an HIV-1 Infected Infant Victoria A. Johnson, 1 Christos J. Petropoulos, 2 Charles R. Woods, 3 J. Darren Hazelwood, 1 Neil T. Parkin, 2 Carol D. Hamilton, 4 and Susan A. Fiscus 5 1 University of Alabama at Birmingham School of Medicine and Birmingham Veterans Affairs Medical Center; 2 ViroLogic, South San Francisco, California; 3 Wake Forest University, Winston-Salem, 4 Duke University Medical Center, Durham, and 5 University of North Carolina at Chapel Hill To confirm the vertical transmission of multidrug-resistant (MDR) human immunodeficiency virus type 1 (HIV-1) and to assess its impact on further evolution of drug-resistant virus in an infant, proviral DNA amplified from infected peripheral blood mononuclear cell cultures was sequenced to identify reverse transcriptase (RT) and protease (PR) mutations. The infant had proviral DNA with evidence of RT mutations (M41L, L74V, and T215Y) and 3 PR substitutions (K20R, M36I, and V82A). After delivery, the mother s proviral DNA had the same substitutions. Phylogenetic analyses of these HIV-1 RT and PR sequences indicated epidemiological linkage. Plasma drug susceptibility was determined by using a recombinant virus assay. Plasma HIV-1 obtained after the infant s birth demonstrated reduced susceptibility to zidovudine and ritonavir. Thus, vertical transmission of MDR HIV-1 was demonstrated in the setting of detectable maternal plasma viremia. Further accumulation of broad MDR in the infant s virus to 3 antiretroviral classes occurred, despite postnatal therapy. Horizontal and vertical transmission of drug-resistant human immunodeficiency virus type 1 (HIV-1) during primary HIV-1 infection has been documented. Hecht et al. [1] first described the horizontal transmission of an HIV-1 variant resistant to multiple reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). In contrast, vertical transmission of multidrugresistant (MDR) HIV-1 has not been described. During an on- Received 31 August 2000; revised 6 February 2001; electronically published 23 April Presented in part: 6th National Conference on Retroviruses and Opportunistic Infections, Chicago, 31 January 4 February 1999 (abstract 266). This project was approved by institutional review boards for the rights of human subjects at the University of Alabama at Birmingham School of Medicine, University of North Carolina at Chapel Hill, and Wake Forest University. Financial support: National Institutes of Health (grants AI-40876, AI , and AI to V.A.J.; AI and HL to C.D.H.); Core Laboratory Research Facilities, University of Alabama at Birmingham (UAB) School of Medicine, UAB Center for AIDS Research (CFAR), and Birmingham Veterans Affairs Medical Center to V.A.J.; Pediatric AIDS Clinical Trials Group (contract 97PVCL06) and University of North Carolina CFAR (P30HD37260) to S.A.F; Metrolina AIDS Project, Ryan White Title IV (#6 H12 HA00061) to C.R.W.; Centers for Disease Control and Prevention (CDC; grant ) and Department of Veterans Affairs via CDC Memorandum of Understanding to C.D.H. Reprints or correspondence: Dr. Victoria A. Johnson, Division of Infectious Diseases, University of Alabama at Birmingham School of Medicine, THT 229, rd Ave. S., Birmingham, AL (vjohnson@ uab.edu). The Journal of Infectious Diseases 2001;183: by the Infectious Diseases Society of America. All rights reserved /2001/ $02.00 going population-based retrospective investigation of perinatal HIV-1 transmission in North Carolina, we identified an HIV- 1 infected infant who had evidence of vertical MDR HIV-1 transmission. We also documented continued viral evolution over time during sequential therapies of the infant. Subjects and Methods Mother. The mother was diagnosed with HIV-1 infection in July Her initial CD4 T lymphocyte count was 281 cells/ mm 3, and percentages remained 28%. She initiated zidovudine (Zdv) at a dose of 500 mg/day in August This was increased to 600 mg/day in June From , she received sequential monotherapy or combined therapies, including Zdv, lamivudine (3TC), stavudine (), didanosine (ddi), indinavir (Idv), and ritonavir (Rtv) (table 1). She had variable medication adherence. Plasma HIV-1 RNA levels were ,380 copies/ml. Although she had no AIDS-defining illnesses, she failed to gain weight and miscarried in June She had a subsequent full-term pregnancy from June 1997 to January 1998; therapies included Zdv/ Rtv/ or Zdv/Rtv/ddI. In November 1997, she stopped ddi because of nausea and restarted on her own, combined with Zdv/ Rtv. Her plasma HIV-1 RNA level was 102,500 copies/ml. Intrapartum intravenous Zdv therapy was added during the infant s delivery in January 1998, in accordance with the Pediatric AIDS Clinical Trials Group (ACTG) protocol 076 regimen [4]. Infant. The infant was born by spontaneous vaginal delivery at 38.4 weeks of gestation; the mother s membranes had ruptured 12 h earlier. The infant received the complete ACTG 076 regimen [4] and never was breast-fed postpartum. The infant tested positive
2 JID 2001;183 (1 June) Vertical Transmission of MDR HIV Table 1. Subject, month/year Mother and infant human immunodeficiency virus (HIV) disease status and antiretroviral history. CD4 T lymphocyte count, cells/mm 3 (%) Plasma HIV-1 RNA level, copies/ml Prior antiretroviral therapy and key events Available peripheral blood specimens Mother 7/ (24) HIV diagnosis; started Zdv monotherapy 2/ (27) Zdv 1/ (24) Zdv 4/94 Plasma a 2/ (22) Zdv 5/95 Plasma a 8/ (20) Patient requested continued monotherapy 11/95 Zdv; 3TC added 2/ (16) Zdv and 3TC 4/ (21) Zdv; patient reports stopping 3TC because of nausea sometime in past several months 6/ (22) 62,320 Zdv; added Idv; 8/96 patient self-decreased dose to twice daily because of nausea; then learned she was pregnant; then miscarried 10/ (20) Zdv; Rtv and added 12/ (21) 527 Zdv, Rtv, and 2/97 18,017 Zdv, Rtv, and 6/ (21) 61,307 Zdv; patient learned she was pregnant and self-decreased Rtv and 9/ (17) 364,380 Zdv; patient convinced to restart Rtv, and ddi added (instead of ) 11/ (14) 102,500 Zdv; patient self-decreased Rtv to 500 mg every 12 h, stopped ddi because of nausea, and self-added back 4/ (14) 134,036 Delivered of child 1/98 with addition of intrapartum intravenous Zdv; had selfdiscontinued Rtv; switched to new regimen of, 3TC, and postpartum 6/ (16) 4889, 3TC, and 7/98 43,996, 3TC, and Plasma a ; PBMC b 8/ (18) 25,303, 3TC, and 10/ , 3TC, and Plasma a ; PBMC b Infant 1/98 Month of birth 2/98 Zdv monotherapy since birth (1/98) including Plasma a ; PBMC b intrapartum intravenous Zdv regimen 3/ (32) 1,751,000 Zdv discontinued; started new regimen of Plasma a ; PBMC b 3TC,, and Nfv 4/ ,391 3TC,, and Nfv 5/98 378,135 3TC,, and Nfv; added Plasma a ; PBMC b 7/ ,550 3TC,, Nfv, and Plasma a ; PBMC b 9/ ,112 3TC,, Nfv, and 10/ ,169 3TC,, Nfv, and Plasma a ; PBMC b NOTE. 3TC, lamivudine; ddi, didanosine;, stavudine; Idv, indinavir; Nfv, nelfinavir;, nevirapine; PBMC, peripheral blood mononuclear cells; Rtv, ritonavir; Zdv, zidovudine;, no data available. a Plasma virus phenotype by Phenosense HIV assay [2]. b PBMC virus genotype by Affymetrix Genechip nucleic acid sequencing [3]. for HIV-1 infection by peripheral blood mononuclear cell (PBMC) coculture and HIV-1 DNA in February 1998, while receiving Zdv monotherapy. Results were confirmed in March Virus load was HIV RNA copies/ml, and CD4 T lymphocyte count was 3090 cells/mm 3 (32% total lymphocytes). In March 1998, Zdv monotherapy was switched to 3TC//nelfinavir (Nfv). Nevirapine () was added in May Despite aggressive therapy, the plasma HIV-1 RNA levels never fell below 76,169 copies/ml. Patient specimens. Sequential peripheral blood specimens were obtained from the mother and the infant. Before delivery, 2 plasma samples were available from the mother (April 1994 and May 1995). After delivery, anticoagulated peripheral blood samples were collected from the mother and the infant and were processed for plasma and virus recovery. Samples obtained nearest to the infant s birth in January 1998 were a July 1998 specimen from the mother and a February 1998 specimen from the infant. Virus load. PBMC HIV-1 DNA was determined by polymerase chain reaction assay, and plasma HIV-1 RNA levels were determined by Amplicor HIV-1 Monitor test (both Roche Diagnostic Systems).
3 1690 Johnson et al. JID 2001;183 (1 June) HIV-1 drug-resistant mutations. The entire protease (PR) coding region and the first 242 codons of reverse transcriptase (RT) were sequenced by GeneChip (Affymetrix) nucleic acid sequence technology by using proviral DNA amplified from PBMC cocultures. Sequences were aligned with reference sequences from the HIV Sequence Database by use of CLUSTALX Multiple Sequence Alignment Program (version 1.8; available at The final sequence alignment was manually adjusted for optimal alignment, and gaps were stripped to ensure that an equal number of bases was compared. Pairwise evolutionary distances were estimated by using Kimura s 2-parameter method, to correct for superimposed substitutions. We constructed phylogenetic trees by the neighbor-joining method. Reliability of topologies was estimated by performing bootstrap analyses with 1000 replicates. HIV-1 drug susceptibility testing. HIV-1 drug susceptibility was determined by the PhenoSense HIV-1 assay (ViroLogic) by using uncultured patient plasma, as described elsewhere [2]. Patient viruses with IC 50 values 2.5-fold above the reference virus IC 50 values were considered to have reduced drug susceptibility for all drugs, except those with clinically determined cutoff values: 1.7- fold for ddi and and 4.5-fold for abacavir. Results Genotypic analyses of HIV-1 RT- and PR-coding regions from mother and infant PBMC-derived viruses. Table 2 depicts HIV-1 RT mutations in PBMC-derived isolates from the mother and infant. At delivery in January 1998, the mother was switched from Zdv//Rtv to 3TC//. Two samples, dated July and October 1998, were available from the mother. The July 1998 virus (GenBank accession no. AF333243) contained the M41L, T215Y, L74V, and V106A mutations, which are associated with reduced susceptibility to Zdv and, ddi, and nonnucleoside RTIs (NNRTIs), respectively. The October 1998 virus (GenBank accession no. AF333244) acquired the L210W, M184V, and K103N mutations, which are associated with reduced susceptibility to Zdv and, 3TC, and the NNRTI class, respectively. Four samples, dated February, May, July, and October 1998, were available from the infant. The February 1998 virus (GenBank accession no. AF333239) contained the M41L, L74V, and T215Y mutations that also were identified in the maternal sample. The infant received postnatal Zdv treatment; therefore, the possibility that M41L and T215Y mutations emerged after birth cannot be eliminated. However, this seems unlikely, given the short duration of postnatal Zdv exposure at the February 1998 time point. Because the infant did not receive ddi therapy before or after birth, the presence of the L74V mutation strongly suggests mother-to-infant transmission of ddi-resistant virus. Therapy was switched to 3TC//Nfv in March The May 1998 virus (GenBank accession no. AF333240) acquired the 3TC resistance mutation 184V, whereas the M41L, L74V, and T215Y RT mutations persisted. Therapy was intensified with. The July 1998 virus Table 2. Mutations in peripheral blood mononuclear cell derived human immunodeficiency virus 1 reverse transcriptase (RT) and protease (PR) coding regions selected by RT inhibitors and PR inhibitors over time (month/year). Coding region, wild type Mother Infant 7/98 10/98 2/98 5/98 7/98 10/98 RT M41 L L L L L L L74 V a V V V V V K103 a N a N V106 a A a A A Y181 a C a C/G/Y M184 a V a V V V L210 W T215 a Y a Y Y Y Y Y PR L10 I I K20 R R R R R R M36 I M/I I I I M/I V82 a A a A A A A A NOTE., Wild type. a Primary drug-selected mutations [5]. (GenBank accession no. AF333241) acquired the NNRTI mutation Y181C, whereas the M41L, L74V, M184V, and T215Y mutations persisted. By October 1998 (GenBank accession no. AF333242), the NNRTI mutations K103N, V106A, and a mixture of Y181C/G/Y were identified, and the nucleoside RTI (NRTI) mutations M41L, L74V, M184V, and T215Y persisted. Table 2 depicts PR substitutions in the HIV-1 isolates derived from PBMC samples from the mother and infant. The mother s July 1998 virus obtained during /3TC/ therapy contained the V82A mutation, despite discontinuation of PR inhibitor (PI) therapy at delivery in January The V82A mutation is strongly associated with Rtv and Idv resistance and possible saquinavir and Nfv cross-resistance. Other substitutions (i.e., L10I, K20R, and M36I) were evident and persisted in October The infant s February 1998 virus also contained the V82A mutation detected in the mother s July 1998 virus sample, even though the infant never received PI therapy. We interpret this as evidence of mother-to-infant transmission of PI-resistant virus. Other substitutions at K20R and M36I also seen in the maternal isolates were identified in the infant s virus, although a third, L10I, was not. Thus, 3 amino acid substitutions associated with resistance to PIs were identified in both the mother and the child at the time points closest to delivery. These substitutions persisted in the infant s virus at all subsequent time points during ongoing Nfv therapy. Phylogenetic relationships of HIV-1 RT and PR coding sequences from mother and infant PBMC-derived viruses. HIV- 1 RT and PR sequences derived from mother and infant isolates were very closely related (i.e., 198% sequence identity). Moreover, phylogenetic analyses revealed a tight cluster of mother and infant viral sequences that was supported by 100% of bootstrap values (figure 1). These data confirm the authenticity of the virus isolates under study.
4 JID 2001;183 (1 June) Vertical Transmission of MDR HIV The infant s February 1998 virus exhibited reduced phenotypic susceptibility to Zdv (31-fold) and Rtv (6-fold). This virus lacked the L74V mutation and was susceptible to ddi, although the PBMC-derived virus at this time point contained the L74V mutation. This likely reflects the presence of an archival form of ddi-resistant virus in PBMC that was no longer circulating in plasma. Discontinuation of maternal ddi therapy 2 months before delivery is consistent with this interpretation. Despite the infant s switch from Zdv monotherapy to /3TC/Nfv in March 1998, plasma HIV-1 RNA levels decreased to only 317,391 copies/ml in April The May 1998 specimen had reduced Zdv susceptibility (4-fold), reduced ddi susceptibility (2-fold), reduced susceptibility (1.8-fold), high-level 3TC resistance (1180-fold), abacavir cross-resistance (5-fold), and persistently reduced Rtv susceptibility (5-fold). The increased phenotypic Zdv susceptibility in the presence of Zdv and 3TC resistance conferring RT mutations (table 2) likely reflected the resensitization of Zdv susceptibility by the M184V mutation. In May 1998, was added to the infant s 3TC//Nfv therapy. By July 1998, there was reduced susceptibility (161-fold), delavirdine (Dlv) cross-resistance (14-fold), and persistently reduced ddi, 3TC, and Rtv susceptibility. By October 1998, broad NNRTI resistance was selected to (1400-fold), Dlv (47-fold), and efavirenz (3-fold). Thus, in!1 year, the infant s virus exhibited significantly reduced susceptibility to NRTIs, NNRTIs, and PIs. Figure 1. Phylogenetic relationships of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and protease coding sequences obtained from mother and infant virus isolates at different time points. Sequences were aligned with subtype B reference sequences by using CLUSTALX Multiple Sequence Alignment Program (version 1.8; available at Phylogenetic tree was constructed using the neighbor-joining method and was rooted by using C.IN.94IN11246 as an out-group. Bootstrap values at each node represent percentage of 1000 bootstrap replicates that support the branching order. Only bootstrap values 70% are shown. Scale bar represents 0.01 nucleotide substitution per site. Maternal-infant specimens collected in July (mother, 07/98) and February 1998 (infant, 02/98) were closest to the infant s birth in January Additional specimens were obtained from the infant in May, July, and October 1998 (infant, 05/98, 07/98, and 10/98) and from the mother in October 1998 (mother, 10/98). Subtype B and C reference sequences from the Los Alamos HIV- 1 Sequence Database are provided as controls: B.US.JRCSF, B.US.JRFL, B.US.MNCG, B.US.NY5CG, B.US.DH123, and C.IN.94IN Drug susceptibility testing of plasma-derived HIV-1 isolates from mother and infant. Table 3 depicts phenotypic testing results from plasma samples obtained from both mother and infant. By delivery in January 1998, the mother had received continuous Zdv therapy for 17 years. Phenotypic testing of 2 early maternal plasma samples collected 45 months (April 1994) and 32 months (May 1995) before delivery showed large reductions in Zdv susceptibility (43-fold and 49-fold, respectively). Discussion This study documents vertical MDR HIV-1 transmission. The infant s virus had multiple RT and PI mutations in the first specimen obtained after birth at a time the child was receiving only postpartum Zdv therapy. PBMC-derived viruses obtained from the mother 6 and 9 months after delivery contained the same RT and PR mutations detected in the infant s first specimen. HIV-1 obtained from the infant after birth exhibited reduced susceptibility to both Zdv and Rtv. Phylogenetic analyses also indicated epidemiological linkage. Taken together, these data support vertical MDR HIV-1 transmission. Because the baby was not breast-fed postpartum, this possible route of perinatal HIV-1 acquisition was highly unlikely. One contributing factor for vertical MDR HIV-1 transmission was the mother s advanced HIV-1 disease stage during pregnancy. Elevated plasma viremia levels are associated with increased risk of vertical HIV-1 transmission [6, 7]. In our study, maternal plasma HIV-1 RNA levels were 1500 copies/ml at least 6 times after 1990 and were 61, ,380 copies/ml in the last 7 months of pregnancy. In contrast to our current practice of treating with triple-drug regimens, this mother began treatment over a decade ago. Consequently, she received sequential 1- and 2- drug regimens that are now known to be suboptimal. Rupture of the mother s placental membranes occurred at least 12 h before delivery, which also increased HIV-1 transmission risk [8]. An-
5 1692 Johnson et al. JID 2001;183 (1 June) Table 3. Mother-to-infant transmission of plasma-derived human immunodeficiency virus with reduced susceptibility to zidovudine (Zdv) and ritonavir (Rtv) by sampling time (month/year). Drug Mother Fold resistance vs. control (NL4-3) a Infant 4/94 5/95 7/98 10/98 2/98 3/98 5/98 7/98 10/98 NRTI Zdv ddc ddi TC Abc NNRTI Dlv Efv PI Rtv Idv Nfv Sqv Therapy at time of sampling Zdv Zdv 3TC 3TC Zdv Zdv 3TC Nfv 3TC Nfv 3TC Nfv NOTE. Values considered to have reduced drug susceptibility are in bold. 3TC, lamivudine; Abc, abacavir; ddi, didanosine; Dlv, delavirdine;, stavudine; Efv, efavirenz; Idv, indinavir; Nfv, nelfinavir; NRTI, nucleoside reverse-transcriptase inhibitor; NNRTI, non-nrti;, nevirapine; PI, protease inhibitor; Sqv, saquinavir. a Virus IC 50 values 2.5-fold greater than reference virus IC 50 values are considered to have reduced drug susceptibility for all drugs, except for those with clinically determined cutoff values: 1.7-fold for ddi and and 4.5-fold for Abc [2]. other contributing factor was medication intolerance and variable adherence to her complex multidrug regimens. Combined Zdv/, which the patient chose to self-administer, may result in pharmacologic antagonism. There also was evidence of maternal Zdv-resistant HIV-1 for at least 3 years before delivery. The mother received prolonged Zdv therapy from 1990 to During her 1998 pregnancy, she was treated with Zdv [9 11]. Zdv administration is recommended during the intrapartum period for HIV-infected pregnant women, regardless of the antepartum regimen or evidence of maternal Zdv resistance [11]. Zdv likely will remain a part of the recommended regimen for perinatal HIV-1 transmission prophylaxis until studies demonstrate comparable safety and activity of other regimens. In our study, Zdv likely was an ineffective barrier to vertical HIV-1 transmission. This supports the potential clinical utility of drug resistance testing in HIV-1 infected pregnant women, at least in women with extensive prior antiretroviral therapy and poorly controlled plasma viremia. This may allow for the identification of active agents and may best prevent vertical HIV-1 transmission. This infant s MDR HIV-1 population continued to accumulate RT mutations during ongoing plasma viremia, which resulted in greater reductions in drug susceptibility. Although the child remains clinically well to date, the long-term consequences of drug resistance to all 3 HIV-1 therapeutic classes are unknown. Future treatment options are also unclear and likely depend on new agent availability. This child s outcome may well differ from reports in previous clinical trials and observational studies [12 14] where more limited drug resistance (i.e., Zdv alone) [14] was evident in infants isolates at the time of vertical HIV-1 transmission. We identified this vertical MDR HIV-1 transmission episode during a review of perinatal HIV-1 transmission in North Carolina [15]. Few instances of vertical drug-resistant HIV-1 transmission were detected, and only this case of vertical MDR HIV-1 transmission was identified, perhaps reflecting minimal prior Zdv or antiretroviral maternal exposure. Although, in the case described, HIV-1 isolates were not obtained from the mother and infant at the exact time of delivery, the viruses were well characterized both genotypically and phenotypically at multiple time points, including determination of the mother s viral resistance status several years before delivery. Phylogenetic analyses also demonstrated the close relationships of HIV-1 RT and PR coding sequences at all time points, which indicated epidemiological linkage. Our retrospective analyses were limited by specimen availability. We did genotypic analyses by using proviral HIV-1 DNA from cultured infected PBMC and phenotypic analyses with uncultured plasma HIV-1 RNA. Despite this, there was only one discordant finding between the PBMC- and plasmaderived viruses at the RT L74 position, as mentioned above. Of note, the viral genotypic and phenotypic approaches used in this study are likely to assess majority or predominant virus populations. Therefore, clinically significant minority populations may have been missed, and the degree of MDR viruses
6 JID 2001;183 (1 June) Vertical Transmission of MDR HIV may have been underestimated. As increasing numbers of HIV- 1 infected women throughout the United States accumulate longer duration of antiretroviral exposure and also elect to become pregnant, it is likely that more cases of vertical MDR HIV-1 transmission will be identified. We have documented vertical MDR HIV-1 transmission in an infant. Future studies should assess prevalence and incidence of MDR HIV-1 in antiretroviral-experienced pregnant women and their impact on vertical HIV-1 transmission. These data encourage investigation of alternative agents and non Zdvcontaining combined regimens among antiretroviral-experienced pregnant women. These studies will require long-term safety monitoring of antiretroviral-experienced mothers and infants for potential combined toxicities. Our study also supports the role of viral drug resistance testing in antiretroviral-experienced pregnant women. Clinical application of such data will be particularly relevant when Zdv-resistant HIV-1 isolates are detectable before and during pregnancy and when maternal plasma viremia is not well controlled. Acknowledgments We thank Beatrice H. Hahn, Feng Gao, and Ruth A. Rhodes (University of Alabama at Birmingham [UAB] School of Medicine) and Colombe Chappey (ViroLogic, South San Francisco, California) for phylogenetic sequence analysis assistance; Jennifer L. Koel, Ruth A. Rhodes, and Clinton D. Nail (UAB School of Medicine), Ada Cachafeiro and Melissa Kerkau (University of North Carolina, Chapel Hill), and Kay Limoli, Wei Huang, Gabrielle Heilek-Snyder, and Jeannette M. Whitcomb (ViroLogic) for technical assistance; Ross McKinney and Megan Valentine (Duke University, Durham, North Carolina) and Dara Garner-Edwards (North Carolina Baptist Hospital, Winston- Salem) for patient care and medical chart review; and Jennifer Bell (UAB School of Medicine) for manuscript preparation. References 1. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV- 1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339: Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44: Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2: Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994;331: Hirsch MS, Brun-Vezinet F, D Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society USA panel. JAMA 2000;283: Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341: Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med 1999;341: Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis 1999;179: Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society USA Panel. JAMA 2000;283: Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep 1998;47(RR-2): Panel on Clinical Practices for Treatment of HIV Infection convened by the US Department of Health and Human Services and the Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at trtgdlns.html. Accessed 5 February Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996;275: Cooper ER, Nugent RP, Diaz C, et al. After AIDS Clinical Trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis 1996;174: Colgrove RC, Pitt J, Chung PH, Welles SL, Japour AJ. Selective vertical transmission of HIV-1 antiretroviral resistance mutations. AIDS 1998;12: Fiscus SA, Adimora AA, Schoenbach VJ, et al. Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. J Infect Dis 1999;180:
Management of NRTI Resistance
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Management of NRTI Resistance David Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationBecause accurate and reproducible phenotypic susceptibility
BRIEF REPORT: CLINICAL SCIENCE Comparison of the Precision and Sensitivity of the Antivirogram and PhenoSense HIV Drug Susceptibility Assays Jie Zhang, MS,* Soo-Yon Rhee, MS,* Jonathan Taylor, PhD, and
More informationPerspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation
Perspective Resistance and Replication Capacity Assays: Clinical Utility and Interpretation Resistance testing has emerged as an important tool for antiretroviral management. Research continues to refine
More information0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920
0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal
More informationResistance Workshop. 3rd European HIV Drug
3rd European HIV Drug Resistance Workshop March 30-April 1 st, 2005 Christine Hughes, PharmD Clinical Associate Professor Faculty of Pharmacy & Pharmaceutical Sciences University of Alberta Tenofovir resistance
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationSupplementary Figure 1. Gating strategy and quantification of integrated HIV DNA in sorted CD4 + T-cell subsets.
Supplementary information HIV reservoir size and persistence are driven by T-cell survival and homeostatic proliferation. Chomont, N., M. El Far, P. Ancuta, L. Trautmann, F. A. Procopio, B. Yassine-Diab,
More informationSomnuek Sungkanuparph, M.D.
HIV Drug Resistance Somnuek Sungkanuparph, M.D. Associate Professor Division of Infectious Diseases Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University Adjunct Professor
More informationReverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review
pissn 2349-2910 eissn 2395-0684 REVIEW Reverse transcriptase and protease inhibitor resistant mutations in art treatment naïve and treated hiv-1 infected children in India A Short Review Dinesh Bure, Department
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationContinuing Education for Pharmacy Technicians
Continuing Education for Pharmacy Technicians HIV/AIDS TREATMENT Michael Denaburg, Pharm.D. Birmingham, AL Objectives: 1. Identify drugs and drug classes currently used in the management of HIV infected
More informationObstetrics and HIV An Update. Jennifer Van Horn MD University of Utah
Obstetrics and HIV An Update Jennifer Van Horn MD University of Utah Obstetrics and HIV Perinatal transmission Testing Antiretroviral therapy Antepartum management Intrapartum management Postpartum management
More informationPediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.
Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV Ernesto Parra, M.D., M.P.H. Adjunct Associate Professor UTHSCSA Department of Pediatrics and Family and Community
More informationThe use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines
The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran, T. Lee, K. Tulloch, L. Sauve, L. Samson, J. Brophy, M. Boucher and D. Money For and
More informationPAEDIATRIC HIV INFECTION. Dr Ashendri Pillay Paediatric Infectious Diseases Specialist
PAEDIATRIC HIV INFECTION Dr Ashendri Pillay Paediatric Infectious Diseases Specialist Paediatric HIV Infection Epidemiology Immuno-pathogenesis Antiretroviral therapy Transmission Diagnostics Clinical
More informationGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
More informationMilan, Italy. Received 15 March 2002; returned 22 July 2002; revised 12 September 2002; accepted 27 September 2002
Journal of Antimicrobial Chemotherapy (2003) 51, 135 139 DOI: 10.1093/jac/dkg016 Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay
More informationSpecial Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel
Special Contribution Questions to and Answers from the International AIDS Society USA Resistance Testing Guidelines Panel In 1996 the International AIDS Society USA convened an international panel of experts
More informationART and Prevention: What do we know?
ART and Prevention: What do we know? Biomedical Issues Trip Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Cornell Medical College New York City ART for Prevention:
More informationTB/HIV/STD Epidemiology and Surveillance Branch. First Annual Report, Dated 12/31/2009
TB/HIV/STD Epidemiology and Surveillance Branch First Annual Report, Dated 12/31/29 This Enhanced Perinatal Surveillance Report is the first annual report generated by the Texas Department of State Health
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:
FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationHIV/AIDS CID 2003:37 (1 July) 113
MAJOR ARTICLE HIV/AIDS Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society USA Panel Martin S. Hirsch,
More informationComprehensive Guideline Summary
Comprehensive Guideline Summary Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents AETC NRC Slide Set Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and
More informationInteractive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1
Antiviral Therapy 10:551 555 Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1 Mina John, Corey B Moore, Ian R James and Simon A Mallal* Centre for Clinical
More informationEvaluation and Management of Virologic Failure
National HIV Curriculum PDF created November 3, 2018, 12:26 am Evaluation and Management of Virologic Failure This is a PDF version of the following document: Section 1: Antiretroviral Therapy Topic 5:
More informationNNRTI Resistance NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated:
More informationDIVISION OF ANTIVIRAL DRUG PRODUCTS (HFD-530) MICROBIOLOGY REVIEW NDA:
Atazanavir (BMS-232632, ATV) Molecular Formula: C 38 H 52 N 6 O 7 H 2 SO 4 Molecular Weight: 704.9 Dosage Form(s): 100/150/200 mg capsule Route(s) of Administration: Oral Pharmacological Category: Indication(s):
More informationCalifornia Perinatal Quality Care Collaborative 2013 Standards of Care for the Prevention of Perinatal HIV Transmission
2013 Revised Edition Authors: David K Hong, MD, Nivedita Srinivas, MD Original Authors: Mary Campbell Bliss, RN, MS, CNS, William Gilbert, MD, Jan Lanouette, MD, Courtney Nisbet, RN, MS, David Wirtschafter,
More informationAIDS, antiretroviral drugs, human immunodeficiency virus, mutations, pol gene, resistance
ORIGINAL ARTICLE Peptide insertions in reverse transcriptase pol gene of human immunodeficiency virus type 1 as a rare cause of persistent antiretroviral therapeutic failure Véronique Schneider 1,Jérôme
More informationRecommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and
Recommendations for Use of Antiretroviral s in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States, June 23, 2004, CDC and updated
More informationTHE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010 The South African Antiretroviral Treatment Guidelines 2010 Goals of the programme Achieve best health outcomes in the most cost-efficient manner
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationDrug-Selected Resistance Mutations and Non-B Subtypes in Antiretroviral-Naive Adults with Established Human Immunodeficiency Virus Infection
MAJOR ARTICLE Drug-Selected Resistance Mutations and Non-B Subtypes in Antiretroviral-Naive Adults with Established Human Immunodeficiency Virus Infection George J. Hanna, 1,a Henri U. Balaguera, 2,a Kenneth
More informationDNA Genotyping in HIV Infection
Frontier AIDS Education and Training Center DNA Genotyping in HIV Infection Steven C. Johnson M.D. Director, University of Colorado HIV/AIDS Clinical Program; Professor of Medicine, Division of Infectious
More informationORIGINAL ARTICLE /j x. Brescia, Italy
ORIGINAL ARTICLE 10.1111/j.1469-0691.2004.00938.x Prevalence of drug resistance and newly recognised treatment-related substitutions in the HIV-1 reverse transcriptase and protease genes from HIV-positive
More informationNobel /03/28. HIV virus and infected CD4+ T cells
Mechanism of HIV drug resistance. Rodrigo Brindeiro / Amilcar Tanuri Laboratório de Virologia Molecular UFRJ 2 -Asso ciate Research Scientist, Internatio nal Center fo r Aids Care and Treatment Programs-ICAP,
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationPreventing Mother to Child HIV Transmission: Are We There Yet?!'
Preventing Mother to Child HIV Transmission: Are We There Yet?!' 2017 Michigan Clincal Nursing Conference for HIV and STD Care May 18, 2017 Frankenmuth MI 1 Theodore B. Jones, MD Maternal Fetal Medicine
More informationDespite the wealth of efficacy data from
OPTIMIZING HIV DRUG THERAPY * John G. Bartlett, MD ABSTRACT The clinical success of highly active antiretroviral therapy (HAART) in the treatment of human immunodeficiency virus disease is one of the great
More informationNOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
NOTICE TO PHYSICIANS DATE: March 10, 2003 TO: FROM: SUBJECT: HIV/AIDS Health Care Providers Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health
More informationClinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy
8 The Open Virology Journal, 2007, 1, 8-13 Clinical Implications of Mutations at Reverse Transcriptase Codon 135 on Response to NNRTI-Based Therapy Harout K. Tossonian 1, Jesse D. Raffa 2, Jason Grebely
More informationThe prevalence of antiretroviral drug resistance in the United States
The prevalence of antiretroviral drug resistance in the United States Douglas D. Richman a,b, Sally C. Morton c, Terri Wrin d, Nicholas Hellmann d, Sandra Berry c, Martin F. Shapiro c,e and Samuel A. Bozzette
More informationPrinciples of Antiretroviral Therapy
Principles of Antiretroviral Therapy Ten Principles of Antiretroviral Therapy Skills Building Workshop: Clinical Management of HIV Infection and Antiretroviral Therapy, 11 th ICAAP, November 21st, 2011,
More informationUse of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH
Use of a Multidisciplinary Care Model for Pregnant Women Living with HIV & Their Infants Sarah McBeth, MD MPH University of Pittsburgh Medical Center Disclosures Presenter has no financial interests to
More informationPediatric HIV Update NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Pediatric HIV Update Christian B. Ramers, MD, MPH Assistant Medical Director, Family Health Centers of San Diego HIV/HCV Distance Education Specialist - NWAETC,
More information2016 Perinatal Treatment Guidelines Update
Mountain West AIDS Education and Training Center 2016 Perinatal Treatment Guidelines Update Shireesha Dhanireddy, MD Associate Professor of Medicine, University of Washington 2 November 2016 This presentation
More informationSubtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients
JAIDS Journal of Acquired Immune Deficiency Syndromes 31:121 127 2002 Lippincott Williams & Wilkins, Inc., Philadelphia Rapid Communications Subtle Decreases in Stavudine Phenotypic Susceptibility Predict
More informationSupplementary information
Supplementary information Dose-response Curve Slope Sets Class-Specific Limits on Inhibitory Potential of Anti-HIV Drugs Lin Shen 1,2, Susan Peterson 1, Ahmad R. Sedaghat 1, Moira A. McMahon 1,2, Marc
More informationAntiviral Therapy 2014; 19: (doi: /IMP2748)
Antiviral Therapy 214; 19:435 441 (doi: 1.3851/IMP2748) Short communication A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationOptimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents
Optimizing 2 nd and 3 rd Line Antiretroviral Therapy in Children and Adolescents Victor Musiime, MBChB, MMED, PhD Senior Lecturer, Makerere University Investigator, Joint Clinical Research Centre (JCRC)
More informationAntiretroviral Therapy During Pregnancy and Delivery: 2015 Update
Frontier AIDS Education and Training Center Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director,
More informationQUANTITATIVE HIV RNA (VIRAL LOAD)
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS QUANTITATIVE HIV RNA (VIRAL LOAD) Policy Number: PDS - 008 Effective Date: October
More informationPredicting Human Immunodeficiency Virus Type 1 Drug Resistance From Genotype Using Machine Learning. Robert James Murray
Predicting Human Immunodeficiency Virus Type 1 Drug Resistance From Genotype Using Machine Learning. Robert James Murray Master of Science School of Informatics University Of Edinburgh 2004 ABSTRACT: Drug
More informationHIV Treatment Update. Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University
HIV Treatment Update Awewura Kwara, MD, MPH&TM Associate Professor of Medicine and Infectious Diseases Brown University Outline Rationale for highly active antiretroviral therapy (HAART) When to start
More informationHIV in in Women Women
HIV in Women Susan L. Koletar, MD The Ohio State University How Many of These Women Have HIV? Answer: I don t really know Google Search: Photos of Groups of Women Pub Med Search: HIV and Women 22,732
More informationCCC ARV Dosing Recommendations for HIV-exposed infants Updated
USERS NOTE: Please note this document does not provide guidance on overall decisionmaking regarding what medication(s) to use for HIV-exposed infants. This document is meant to facilitate ARV dosing for
More informationPediatric Antiretroviral Resistance Challenges
Pediatric Antiretroviral Resistance Challenges Thanyawee Puthanakit, MD The HIVNAT, Thai Red Cross AIDS research Center The Research Institute for Health Science, Chiang Mai University Outline The burden
More informationHuman immunodeficiency virus (HIV) can be HJOG. HIV infection in pregnancy: Analysis of twenty cases. Research. Abstract
HJOG An Obstetrics and Gynecology International Journal Research HIV infection in pregnancy: Analysis of twenty cases Kasioni Spiridoula 1, Pappas Stefanos 2, Vlachadis Nikolaos 3, Valsamidi Irene 1, Stournaras
More informationRNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis
RNA PCR, Proviral DNA and Emerging Trends in Infant HIV Diagnosis 1 B R E N D A N M C M U L L A N I N F E C T I O U S D I S E A S E S, S Y D N E Y C H I L D R E N S H O S P I T A L S C H O O L O F W O
More informationPRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES
PRINCIPLES and TRENDS in MANAGEMENT of HIV DISEASE: PROBLEMS OF DRUG RESISTANCE in VIRUSES of DIFFERENT SUBTYPES Mark A. Wainberg McGill University AIDS Centre Jewish General Hospital Montreal, Quebec,
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationDidactic Series. Archive Genotype Resistance Testing in the Setting of Regimen Switching
Didactic Series Archive Genotype Resistance Testing in the Setting of Regimen Switching Craig Ballard, Pharm.D., AAHIVP UCSD Medical Center Owen Clinic June 11, 2015 ACCREDITATION STATEMENT: University
More informationHIV in Pregnancy. In Practice. Cheryl Roth Pauline F. Hrenchir Christine J. Pacheco
In Practice Photo istock Collection / thinkstockphotos.com IImagine this scenario: You are working on a Saturday afternoon when a woman comes into the obstetrics triage unit. She is pregnant for the fourth
More informationRegister for notification of guideline updates at
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States Visit the AIDSinfo website
More informationObstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives
Review Article Indian J Med Res 119, June 2004, pp 217-237 Obstacles to successful antiretroviral treatment of HIV-1 infection: problems & perspectives Simon J. Potter, Choo Beng Chew*, Megan Steain, Dominic
More informationCriteria for Oral PrEP
Oral PrEP New Drugs Roy M. Gulick, MD, MPH Chief, Division of Infectious Diseases Professor of Medicine Weill Medical College of Cornell University New York City Safe Criteria for Oral PrEP Penetrates
More informationManagement of the HIV-Exposed Infant
Management of the HIV-Exposed Infant Katherine Knapp, MD Medical Director, Perinatal Program Department of Infectious Diseases St. Jude Children s Research Hospital Disclosures No conflicts of interest
More informationLiver Toxicity in Epidemiological Cohorts
SUPPLEMENT ARTICLE Liver Toxicity in Epidemiological Cohorts Stephen Becker Pacific Horizon Medical Group, San Francisco, California Hepatotoxicity has been demonstrated to be associated with antiretroviral
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationVisit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman
Visit Reason: Positive Pregnancy Test. HIV Treatment in the Childbearing Woman Thi-Thi Nguyen, PharmD, BCPS, AAHIVP Mountain Plains AIDS Education and Training Center Conference August 13th, 2015 1 Objectives
More informationOccupational and Non- Occupational HIV Post-exposure Prophylaxis
Occupational and Non- Occupational HIV Post-exposure Prophylaxis Amy V. Kindrick, MD, MPH National Clinicians Post-Exposure Prophylaxis Hotline (PEPline) University of California, San Francisco San Francisco
More informationCUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA. Date
CUMULATIVE PERINATAL HIV EXPOSURE, AUSTRALIA 350 300 250 Number 200 150 100 50 0 1/01/1997 1/01/1998 1/01/1999 1/01/2000 31/12/2000 31/12/2001 31/12/2002 Date July 2004 Reported number of perinatally exposed
More informationAntiretroviral Prophylaxis and HIV Drug Resistance. John Mellors University of Pittsburgh
Antiretroviral Prophylaxis and HIV Drug Resistance John Mellors University of Pittsburgh MTN Annual 2008 Outline Two minutes on terminology Origins of HIV drug resistance Lessons learned from ART Do these
More informationDATA SHEET. Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter calf thymus DNA.
Viral Load DNA >> Standard PCR standard 0 Copies Catalog Number: 1122 Lot Number: 150298 Release Category: A Provided: 500 µl of 5.6 mm Tris HCl, 4.4 mm Tris base, 0.05% sodium azide 0.1 mm EDTA, 5 mg/liter
More informationTransmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System
Transmission Fitness of Drug- Resistant HIV Revealed in the United States National Surveillance System Joel O. Wertheim 1,2, Alexandra M. Oster 3, Jeffrey A. Johnson 3, William M. Switzer 3, Neeraja Saduvala
More informationEpatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici. Ivana Maida
Epatite B: fertilità, gravidanza ed allattamento, aspetti clinici e terapeutici Ivana Maida Positivity for HBsAg was found in 0.5% of tested women In the 70s and 80s, Italy was one of the European countries
More informationTitle. HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in
Title HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance October 13, 2004 Authors SY Rhee
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationPrevention of Perinatal HIV Transmission
Prevention of Perinatal HIV Transmission Emily Adhikari, MD Division of Maternal-Fetal Medicine Obstetrics and Gynecology University of Texas Southwestern Medical Center February 20, 2018 None Understand
More informationHIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital
HIV-1 Subtypes: An Overview Anna Maria Geretti Royal Free Hospital Group M Subtypes A (1, 2, 3) B C D F (1, 2) G H J K Mechanisms of HIV-1 genetic diversification Point mutations RT error rate: ~1 per
More informationMalaysian Consensus Guidelines on Antiretroviral Therapy Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh
Malaysian Consensus Guidelines on Antiretroviral Therapy 2017 Cheng Joo Thye Hospital Raja Permaisuri Bainun Ipoh Acknowledgement Table of contents Evolution of when to initiate therapy ART improves survival
More informationCase Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.
Case Study Dr Sarah Sasson Immunopathology Registrar HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital Case 1: Case 1: 45F in Cameroon Cameroon HIV+ Presents with cutaneous
More informationART for HIV Prevention:
ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral
More informationPerinatal HIV Exposure: Antiretroviral Management. Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident
Perinatal HIV Exposure: Antiretroviral Management Danielle McDonald, PharmD PGY-2 Pediatric Pharmacotherapy Resident A presentation for HealthTrust Members June 1, 2018 Learning Objectives for Pharmacists
More informationNational AIDS Treatment Advocacy Project
National AIDS Treatment Advocacy Project T-20 (first fusion inhibitor) Nelfinavir 12 month data Latent HIV reservoir (integrated proviral DNA), CSF and protease inhibitors: preliminary data (ritonavir/saquinavir
More informationHIV/AIDS Prenatal Care for HIV+ Mothers. 1. Algorithm for Prenatal Screening & Care (Antepartum)
7/10/18 njm 1. Algorithm for Prenatal Screening & Care (Antepartum) 2. Algorithm for Prenatal HIV Screening and Care (Mother refuses screening) 3. Algorithm for Intrapartum Care 4. Prenatal Care for HIV+
More informationQuick Reference Guide to Antiretrovirals. Guide to Antiretroviral Agents
Author: Malte Schütz, MD June 1, 2002 Quick Reference Guide to Antiretrovirals Regular updates to this publication are posted on the Medscape Web site at http://hiv.medscape.com/updates/quickguide. Please
More informationSupplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study
Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study Study Almeida 2011 Auld 2011 Bassett 2012 Bastard 2012 Boulle 2008 (a) Boulle 2008 (b) Boulle 2010 Breen
More informationAntiviral Therapy 2011; 16: (doi: /IMP1851)
Antiviral Therapy 2011; 16:925 929 (doi: 10.3851/IMP1851) Short communication Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure
More informationHIV medications HIV medication and schedule plan
Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationINTERPROFESSIONAL PROTOCOL - MUHC
INTERPROFESSIONAL PROTOCOL - MUHC Medication included No Medication included THIS IS NOT A MEDICAL ORDER Title: PREVENTION OF MATERNAL TO INFANT HIV INFECTION Intrapartum, Peripartum, and Postpartum Antiretroviral
More informationWhat s New. In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group
What s New In The 2016 Perinatal HIV Treatment Guidelines? Provided by CDC s Elimination of Perinatal HIV Transmission Stakeholders Group Guidelines for our Online Meeting Room You will be listening to
More informationTerapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos
Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos (Antiretroviral Therapy Present and Future Prospects of Antiretroviral Drugs in Initial and Salvage Therapy)
More informationWHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES?
WHAT S NEW IN THE 2015 PERINATAL HIV GUIDELINES? Today s Webinar will be starting soon For the audio portion of this meeting: Dial 1-855-702-5382 Enter participant code 596-825-4701# Guidelines for online
More informationPharmacological considerations on the use of ARVs in pregnancy
Pharmacological considerations on the use of ARVs in pregnancy 11 th Residential Course on Clinical Pharmacology of Antiretrovirals Torino, 20-22 January 2016 Prof. David Burger, PharmD, PhD david.burger@radboudumc.nl
More informationBJID 2001; 5 (August) 177. count and a mild decrease in viral load, patients tended to have an inverse correlation between the CD 4. counts [7].
BJID 2001; 5 (August) 177 Evaluation of Viral Resistance to Reverse Transcriptase Inhibitors (RTI) in HIV-1- Infected Patients Before and After 6 Months of Single or Double Antiretroviral Therapy Carlos
More information